Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized B-cell tailored dosing of ocrelizumab in relapsing-remitting multiple sclerosis
NL-OMON60265Phase 4Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ocrelizumab in multiple sclerosis (MS) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Confirmed relapse-free proportion at 96 weeks and No new or enlarging T2 MRI lesions at 96 weeks. Started Mar 2022; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON60265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60265.